PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16619577-0	2006	Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.	Irinotecan	30-36	proteasome 26S subunit, non-ATPase 1	Homo sapiens	51-54	
16619577-9	2006	CONCLUSION: Biweekly CPT-11 plus CDDP was feasible for S-1- and paclitaxel-refractory metastatic gastric cancer, with moderate activity and favorable toxicity.	Irinotecan	21-27	proteasome 26S subunit, non-ATPase 1	Homo sapiens	55-58